Global Recurrent Glioblastoma Multiforme Treatment Market, by Treatment (Oral Medication, Radiosensitizers, Nitrosoureas Drugs, and Chemotherapy ), by Type (Grade II or Grade III, Grade IV, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 369.6 million in 2020 and is expected to exhibit a CAGR of 6.14% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Key players are involved in strategic collaborations to expand their market presence. For instance, in May 2017, DelMar Pharmaceuticals entered into a collaboration agreement with PRA Health Sciences, a contract research organization (CRO), to conduct phase III trials of VAL-083 for the treatment of recurrent glioblastoma multiforme. A global leader of CRO, PRA Health Sciences, provides outsourced clinical development services to the biotechnology as well as pharmaceutical industries.
For instance, in January 2020, a bevacizumab biosimilar, Zirabev, was launched by Pfizer in the U.S. for the treatment of recurrent GBM. Zirabev represents Avastin, which is priced at US$ 61.34 per 10 mg at Wholesale Acquisition Cost (WAC). FDA approved the biosimilar in June 2019 for the treatment of recurrent or metastatic NSCLC, metastatic cell carcinoma, metastatic colorectal cancer, recurrent glioblastoma multiforme, and persistent/recurrent or metastatic cervical cancer.
Recurrent Glioblastoma Multiforme Treatment Market - Impact of Coronavirus (Covid-19) Pandemic
The COVID-19 outbreak has immensely affected the recurrent glioblastoma multiforme treatment market growth. According to the Centers for Disease Control and Prevention (CDC), patients aged 65 years & above and those with hysterical comorbidities are considered at high risk of being affected with COVID-19 infection. Therefore, based on these risk factors, it is recommended to the glioblastoma multiforme patients with recurrent GBM to be strongly considered for hypofractionated RT regimens. The recurrent GBM industry is likely to get impacted due to COVID-19 pandemic and the treatments for this disease will evolve in the near future.
Browse 26 Market Data Tables and 28 Figures spread through 160 Pages and in-depth TOC on Recurrent Glioblastoma Multiforme Treatment Market, By Treatment (Oral Medication, Radiosensitizers, Nitrosoureas Drugs, and Chemotherapy ), by Type (Grade II or Grade III, Grade IV, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Forecast to 2027”
To know the latest trends and insights related to recurrent glioblastoma multiforme treatment market, click the link below:
https://www.coherentmarketinsights.com/market-insight/glioblastoma-multiforme-market-682
Key players in the market are adopting several strategies such as mergers & acquisitions, collaborations, and joint ventures to strengthen their position in the global market. For instance, in October 2019, Advaxix and UCLA entered into a research agreement for the development of GBM immunotherapy products. The company aims to conduct preclinical studies assessing the Lm technology of UCLA in mouse tumor models of glioblastoma multiforme.
Key Takeaways of the Global Recurrent Glioblastoma Multiforme Treatment Market:
- The global recurrent glioblastoma multiforme treatment market is expected to exhibit a CAGR of 6.14% during the forecast period (2020-2027), owing to rising prevalence of seizures and the advancements in treatment & partnerships among market players
- Among type, the grade IV segment accounted for significant revenue share, owing to increasing prevalence of such conditions. For instance, according to the American Association of Neurological Surgeons (AANS), the prevalence of GBM accounts for around 52% of all the primary brain tumors.
- Major players operating in the global recurrent glioblastoma multiforme treatment market include GlaxoSmithKline plc., AstraZeneca, F. Hoffman-La Roche, Ltd., Pfizer, Inc., Merck & Co., Inc., Vascular Biogeneics, AngioChem, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Cantex Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Cavion LLC, Coherus BioSciences, Inc., Eisai, Eli Lilly and Company, Cortice Biosciences, Inc., EnGeneIC Ltd., GenSpera, Inc., ERC Belgium SA, Genzyme Corporation, ImmunoCellular Therapeutics, Ltd., and GW Pharmaceuticals Plc.
